PCSA

1.5607.69%
RL

Russell L. Skibsted

Chief Financial Officer

Mr. Russell L. Skibsted, M.B.A. has been the Chief Financial Officer of Processa Pharmaceuticals, Inc. since July 17, 2024. He served as Executive Vice President, Chief Financial Officer and Chief Business Officer at Rockwell Medical, Inc. since September 15, 2020, until 2022. He served as Senior Vice President and Chief Financial Officer at Alimera Sciences, Inc. since January 09, 2023, until January 2024. Mr. Skibsted is responsible for business development, financial operations and Investor Relations for the Company and oversees the Finance and Accounting, Legal and Compliance and Human Resources and Administration functions. He served as Chief Financial Officer of AgeX Therapeutics, Inc since July 2017 until May 2020. He joined Lineage Cell Therapeutics, Inc. in 2015. Mr. Skibsted was the Chief Financial Officer of Lineage Cell Therapeutics, Inc. (Formally known as BioTime, Inc.) since November 16, 2015, until January 7, 2019. Mr. Skibsted served as the Chief Financial Officer of OncoCyte Corporation since November 2015 until November 2017. He is a seasoned executive in finance, acquisitions, Partnering, marketing and operations, with companies ranging from start-ups to a Fortune 5, with Chief Financial Officer responsibilities in public life science companies. He has significant private equity, public market, operations and transaction with both public and private companies. He served as an Acting Chief Financial Officer of Asterias Biotherapeutics, Inc. since March 14, 2016, until November 2016. He joined Lineage Cell Therapeutics, Inc. from Proove Biosciences, Inc. where he served as Chief Financial Officer since 2014 until November 2015. He served as the Chief Financial Officer and Executive Vice President at Pharmagen, Inc., from June 2014 to June 30, 2014. From 2013 to 2014, Mr. Skibsted served as Managing Director and Chief Financial Officer of RSL Ventures, where he provided financial consulting services to public and private companies in the life sciences sector. He served as the Chief Financial Officer and Senior Vice President of Aeolus Pharmaceuticals Inc., from February 2011 to May 31, 2013 and also served as its Principal Accounting Officer and Secretary until May 31, 2013. He served as the Chief Financial Officer and Vice President of Talon Therapeutics, Inc. from November 15, 2004, to January 1, 2006 and as its Secretary from November 2004 to January 1, 2006. where he led the process of bringing it public and completed two financings. He served as Senior Vice President and Chief Business Officer of Spectrum Pharmaceuticals, Inc. from 2006 to 2009. At Spectrum, he led global strategy, mergers and acquisitions, licensing, fund raising and Investor Relations. Prior to BioTime, Mr. Skibsted served as CFO or Chief Business Officer for several public and private life science companies, including Hana Biosciences. During his tenure at Spectrum, he completed numerous financings, including one of the 2008 largest biopharma Partnering transactions for a non-platform technology. He was a Partner and served as the Chief Financial Officer of Asset Management Ventures. Mr. Skibsted served as a Partner and Chief Financial Officer of Asset Management Company from 2000 to 2004 where he oversaw the financial and administrative functions, public and private portfolios and aviation operations. He worked at GE Capital Services' Structured Finance Group, running business development in the western United States. As a Member of the Corporate Development team at Pinkerton's Inc. where he spearHeaded the implementation of its acquisitions and corporate Partnering department. He was a Principal at NewCap Partners, Inc. He co-founded two successful startups in the real estate industry. He managed the Johnson office and the Franklin & Catherine Johnson Foundation. Mr. Skibsted served as a Director of TCSI Corporation since October 2001. He holds a BA in Economics from Claremont McKenna College and an MBA from the Stanford Graduate School of Business.

Positions